Step 1 topics → Hematology and Oncology → Autoimmune Hemolytic Anemia (Warm and Cold)

Autoimmune Hemolytic Anemia (Warm and Cold)

USMLE Step 1 trap: Confuses cold AIHA antibody class (IgM) with warm AIHA antibody class (IgG). Cold AIHA is mediated by IgM antibodies that activate complement, leading to intravascular hemolysis or extravascular hepatic clearance.

Autoimmune hemolytic anemia (AIHA) is a category of hemolytic anemia where the immune system produces antibodies against self red blood cell antigens, leading to accelerated RBC destruction. The two main types — warm and cold AIHA — differ in antibody class, mechanism of hemolysis, causes, Coombs pattern, and treatment. USMLE Step 1 tests this concept from multiple angles: pure recall (IgG vs IgM, splenic vs hepatic/intravascular clearance), clinical application (matching a patient presentation to warm vs cold type), and passage interpretation (reading a Coombs result and determining what antibody or complement component is driving it).

The trickiest part of this topic is that students often conflate the two types, especially on Coombs interpretation. Warm AIHA gives a positive direct Coombs for IgG because IgG stays bound at body temperature. Cold AIHA gives a positive direct Coombs for complement (C3d) only — not IgG — because the IgM antibody binds at cold peripheral temperatures, activates complement, then elutes off when blood returns to core body temperature. If you don't understand why the Coombs patterns differ, you'll miss questions that hinge on that distinction. The exam will absolutely give you a Coombs result and ask you to interpret it.

The other high-yield trap on USMLE Step 1 is management: steroids work for warm AIHA but are largely ineffective for cold AIHA. Students who memorize 'steroids for AIHA' without the warm/cold distinction will get burned. Similarly, the infectious associations matter — Mycoplasma pneumoniae is a classic but frequently forgotten cause of cold AIHA (anti-I antibodies), while EBV causes cold AIHA via anti-i antibodies. Knowing both is fair game.

From real student decks
86%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: Cold AIHA is mediated by IgG antibodies like warm AIHA.
Right: Cold AIHA is mediated by IgM antibodies that activate complement, leading to intravascular hemolysis or extravascular hepatic clearance.
Cold AIHA is driven by IgM, not IgG — this distinction matters mechanistically. IgM is a large pentameric antibody that binds RBC surface antigens at cold temperatures in peripheral tissues, then powerfully activates the classical complement cascade. Because IgM stays on the RBC only briefly before eluting at warmer core temperatures, the downstream effect is complement-mediated hemolysis (intravascular) or C3b-opsonized clearance in the liver (extravascular hepatic) — neither of which applies to IgG-mediated warm AIHA, which uses splenic macrophages.
Common mistake
Wrong: Students associate cold AIHA with EBV only, forgetting Mycoplasma pneumoniae.
Right: Cold AIHA is classically associated with Mycoplasma pneumoniae (anti-I antibodies) and EBV/infectious mononucleosis (anti-i antibodies).
EBV is memorable, but Mycoplasma pneumoniae is actually the more classic board answer for cold AIHA. Mycoplasma produces anti-I antibodies (targeting the adult 'I' antigen on RBCs), while EBV produces anti-i antibodies (targeting the fetal 'i' antigen). The exam may present a young patient with atypical pneumonia (Mycoplasma) who develops anemia in cold weather — recognizing both associations prevents you from defaulting to EBV every time.
Common mistake
Wrong: Both warm and cold AIHA give a positive direct Coombs test for IgG.
Right: Warm AIHA gives a positive direct Coombs for IgG, while cold AIHA gives a positive direct Coombs for complement (C3d) only, since IgM elutes off at body temperature.
The key is understanding that the direct Coombs test detects what's actually coating the RBC surface. In warm AIHA, IgG stays on the RBC at body temperature, so the DAT is IgG-positive. In cold AIHA, the IgM antibody binds at cold temperatures, activates complement, then elutes off when blood returns to 37°C — but complement fragments (especially C3d) remain covalently attached to the RBC surface. So the DAT in cold AIHA is C3d (complement)-positive and IgG-negative. A question giving you a 'complement-positive only' DAT is pointing at cold AIHA.
Common mistake
Wrong: Steroids are first-line treatment for cold AIHA as they are for warm AIHA.
Right: Cold AIHA is treated primarily by cold avoidance and treating the underlying cause; steroids are largely ineffective, and rituximab is used for refractory cases.
Steroids work in warm AIHA by reducing macrophage Fc-receptor activity and decreasing autoantibody production — both mechanisms are irrelevant in cold AIHA. In cold AIHA, the pathology is IgM-mediated complement activation, not Fc-mediated splenic clearance, so steroids don't address the mechanism. The correct approach is cold avoidance (keeps IgM from binding in the first place) and treating the underlying cause (e.g., antibiotics for Mycoplasma); rituximab targets B cells that produce the pathologic IgM in refractory cases.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify the antibody class (IgG) responsible for warm AIHA, explain why hemolysis occurs extravascularly in the spleen, and name common underlying causes (SLE, CLL, drugs, idiopathic).
  2. Identify the antibody class (IgM) responsible for cold AIHA, explain how complement activation drives hemolysis, and recall the classic infectious associations — Mycoplasma pneumoniae (anti-I) and EBV/mono (anti-i).
  3. Interpret a direct Coombs (DAT) result in the context of warm vs cold AIHA: warm AIHA is IgG-positive, while cold AIHA is complement (C3d)-positive and IgG-negative, and explain why the patterns differ.
  4. Select the correct first-line treatment for warm AIHA (steroids, with splenectomy or rituximab for refractory cases) versus cold AIHA (cold avoidance and treating the underlying cause; steroids are ineffective; rituximab for refractory cases).

Can you avoid these mistakes?

A 35-year-old woman with SLE presents with fatigue and jaundice. Direct Coombs test is positive for IgG, negative for complement. Peripheral smear shows spherocytes. Where does RBC destruction primarily occur, and what is the first-line treatment?
A 22-year-old man develops anemia two weeks after a respiratory illness with patchy infiltrates on CXR. He notices his fingers turn blue in cold weather. Direct Coombs is positive for C3d only, negative for IgG. What antibody class is responsible for his hemolysis, and what are the two most likely infectious triggers for this presentation?
A patient has cold AIHA refractory to supportive management. A fellow suggests starting prednisone. Why is this approach unlikely to work, and what is the mechanism-based explanation for steroid failure in this condition?
You are given two direct Coombs results: Patient A is positive for IgG only; Patient B is positive for C3d only. Match each result to warm or cold AIHA and explain what happens to the antibody in Patient B that accounts for why IgG is not detected.

Related topics

Hemolytic Anemia — Intravascular vs Extravascular Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →